Analysts Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) PT at $27.40

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have earned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $27.40.

A number of equities research analysts have issued reports on the stock. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. The Goldman Sachs Group decreased their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday.

Kestra Medical Technologies Trading Up 0.4%

Kestra Medical Technologies stock opened at $25.44 on Wednesday. The company has a 50 day moving average price of $21.20 and a 200 day moving average price of $22.78. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -6.42 and a beta of 0.83.

Insider Activity

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 45,000 shares of company stock worth $927,150. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. raised its holdings in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $72,000. BNP Paribas Financial Markets raised its holdings in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.